New drug target can break down cancer's barrier against treatment

July 27, 2014, Cancer Research UK

Cancer research UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective, according to research published in Nature.

The team at Barts Cancer Institute, part of Queen Mary University of London, have found that a molecule, called focal adhesion kinase (FAK), signals the body to repair itself after chemotherapy or radiotherapy, which kill by damaging DNA. When the researchers removed FAK from blood vessels that grew in melanoma or lung models, both chemotherapy and radiation therapies were far more effective in killing the tumours.

The researchers also studied samples taken from lymphoma patients. Those with low levels of FAK in their blood vessels were more likely to have complete remission following treatment. This suggests that developing drugs to strike out FAK in cancer blood vessels may boost cancer treatments and prevent cancer from coming back.

Dr Bernardo Tavora, lead author on the paper from the Barts Cancer Institute, said: "This work shows that sensitivity to cancer treatment is related to our own body mistakenly trying to shield the cancer from cell-killing effects caused by radiotherapy and chemotherapy.

"Although taking out FAK from blood vessels won't destroy the cancer by itself, it can remove the barrier cancer uses to protect itself from treatment."

Cells lining the blood vessels send chemical signals, called cytokines, to the tumour to help it resist DNA damage and to recover. The researchers demonstrated that this process requires FAK in order to work, and without it, these signals are never sent – making the tumour more vulnerable to DNA damaging therapy.

Dr Kat Arney, Cancer Research UK's science communications manager, said: "This exciting research may have cracked how healthy cells in the are protecting against cancer treatments. This research was only done in mice, but it gives real hope that we can boost the effectiveness of cancer medicine and sensitise cancers to the drugs we have."

Explore further: Finding the Achilles' Heel of ovarian tumor growth

More information: Tavora et al. Endothelial-FAK targeting sensitises tumours to DNA-damaging therapy. Nature 2014. DOI: 10.1038/nature13541

Related Stories

Finding the Achilles' Heel of ovarian tumor growth

June 19, 2014
A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that small molecule inhibitors ...

Viral therapy could boost limb-saving cancer treatment

July 22, 2014
Viruses designed to target and kill cancer cells could boost the effectiveness of chemotherapy to the arms and legs and help avoid amputation, a new study reports.

FAK helps tumor cells enter the bloodstream

January 20, 2014
Cancer cells have something that every prisoner longs for—a master key that allows them to escape. A study in The Journal of Cell Biology describes how a protein that promotes tumor growth also enables cancer cells to use ...

Starving pancreatic cancer before it has a chance to feast

June 23, 2014
(Medical Xpress)—Pancreatic cancer's low survival rate gives researchers from The University of Kansas Cancer Center even more reason to find a way to prevent and treat the hard-to-detect cancer. Drs. Snigdha Banerjee, ...

Cancer therapy may be too targeted

March 16, 2014
Researchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly ...

Wake-up call for more research into cell metabolism

July 9, 2014
More scientific research into the metabolism of stromal support cells and immune cells – and the role of the metabolism of these cell types in the development of diseases – could open new therapeutic avenues for diabetes, ...

Recommended for you

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

Gene screening technique helps identify genes involved in a fatty liver-associated liver cancer

October 17, 2018
With an estimated twenty-thousand protein-coding genes in the human genome, pinpointing a specific gene or pathway responsible for a particular disease can be like finding a needle in the proverbial haystack. This has certainly ...

Scientists zero in on ways to boost colorectal cancer screening

October 17, 2018
A comprehensive analysis by University of North Carolina Lineberger Comprehensive Cancer Center researchers evaluated more than 70 clinical studies to identify some of the most effective methods for boosting U.S. colorectal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.